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What is the key question?: 
Several studies have suggested that airborne transmission of P. aeruginosa among patients 
with cysitc fibrosis (CF) is feasible, however, it is unclear how far cough generated aerosols 
travel or how long they remain viable in the airborne phase. 
 
What is the bottom line?: 
Using two validated cough aerosol sampling systems to measure the viability of                    
P. aeruginosa in droplet nuclei we demonstrate that patients with CF produce cough aerosols 
containing viable organisms that are capable of travelling up to 4-metres and persisting in the 
air for up to 45-minutes. 
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Why read on? 
Data presented here challenge current CF infection control practices of separating patients by 
1-to-2 metres to prevent cross-infection by respiratory bacteria; suggesting a re-examination 
of current infection control practices within the CF community is needed. 
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ABSTRACT (246 words) 
Background: Person-to-person transmission of respiratory pathogens, including 
Pseudomonas aeruginosa, is a challenge facing many cystic fibrosis (CF) centres. Viable              
P. aeruginosa are contained in aerosols produced during coughing, raising the possibility of 
airborne transmission. 
Methods: Using purpose-built equipment, we measured viable P. aeruginosa in cough 
aerosols at 1, 2, and 4-metres from the subject (distance) and after allowing aerosols to age 
for 5, 15, and 45-minutes in a slowly rotating drum to minimise gravitational settling and 
inertial impaction (duration). Aerosol particles were captured and sized employing an 
Anderson Impactor and cultured using conventional microbiology. Sputum was also cultured 
and lung function and respiratory muscle strength measured. 
Results: Nineteen patients with CF, mean age 25.8 (SD:9.2) years, chronically infected with 
P. aeruginosa, and 10 healthy controls, 26.5 (8.7) years, participated. Viable P. aeruginosa 
were detected in cough aerosols from all patients with CF, but not from controls; travelling  
4-metres in 17/18 (94%) and persisting for 45-minutes in 14/18 (78%) of the CF group. 
Marked inter-subject heterogeneity of P. aeruginosa aerosol colony counts was seen and 
correlated strongly (r=0.73-0.90) with sputum bacterial loads. Modelling decay of viable       
P. aeruginosa in a clinic room suggested that at the recommended ventilation rate of two air 
changes per hour almost 50-minutes were required for 90% to be removed after an infected 
patient left the room. 
Conclusions: Viable P. aeruginosa in cough aerosols travel further and last longer than 
recognised previously, providing additional evidence of airborne transmission between 
patients with CF. 
5 
INTRODUCTION 
Communicable respiratory infections are an important cause of mortality and morbidity and 
result in healthcare costs worth billions of dollars.[1, 2] The person-to-person transmission of 
respiratory pathogens may occur by three key routes: contact transmission where infectious 
respiratory secretions spread by direct contact or indirectly through a contaminated 
intermediate object or person; droplet transmission where large infectious droplets travel 
directly over short distances from the respiratory tract to deposit onto mucosal surfaces (e.g. 
nasal and conjunctival mucous membranes), and airborne transmission involving 
dissemination of small droplet nuclei within the respirable size range that remain infectious 
over time and distance and are inhaled by susceptible individuals.[3] Airborne transmission 
may pose a significant risk for hospital-acquired respiratory infection,[4] with evidence that it 
is an important mode of acquisition for many respiratory infections, including 
Mycobacterium tuberculosis (TB) and Bordetella pertussis.[5, 6] 
 
Cystic fibrosis (CF) is the most common life-limiting autosomal-recessive disorder in 
Caucasians with most affected persons dying in their third-to-fourth decade from respiratory 
failure complicating chronic pulmonary infections.[7] Pseudomonas aeruginosa is the most 
common pathogen in CF lung disease and once infection is established there is an accelerated 
decline in lung function, quality of life and survival.[8, 9] While many patients with CF 
acquire P. aeruginosa sporadically from the environment, molecular-typing studies show 
shared strains are common in some CF centres, suggesting person-to-person transmission 
may also be occurring.[10, 11] In Australia, P. aeruginosa strains AUST-01 and AUST-02 
are responsible for 40% of chronic infections,[11] and are associated with worse clinical 
outcomes and increased treatment requirements.[11, 12] The mechanisms of cross-infection 
in CF are unknown. However, despite CF centres implementing contact and droplet 
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transmission control measures, P. aeruginosa cross-infection continues [11, 13, 14] and is 
only interrupted by implementing strict patient segregation policies.[15, 16] 
 
It seems that a plausible mechanism of transmission between patients is the airborne route. 
Indeed, patients with CF infected with P. aeruginosa produce droplet nuclei containing viable 
bacteria.[17] Furthermore, studies using air sampling in CF clinical settings have 
demonstrated viable P. aeruginosa after physiotherapy and in corridors outside inpatient 
cubicle rooms housing patients with shared strain P. aeruginosa infection.[18, 19] Others 
have also suggested that airborne transmission is feasible, with shared and mucoid P. 
aeruginosa strains having a survival advantage.[20, 21] However, methods used in previous 
studies were unable to demonstrate how long viable bacteria were present in aerosols, or how 
far they could travel from the original source. We therefore sought to enhance understanding 
of P. aeruginosa aerosol production in CF in order to (i) determine the duration and distance 
of viable cough aerosols, (ii) identify the factors influencing pathogen viability, and to (iii) 
understand the effects of room ventilation on controlling the duration of viable airborne P. 
aeruginosa. 
 
METHODS 
Subjects 
Patients with CF (n=19) aged >12-years old and chronically infected with P. aeruginosa were 
recruited from the Royal Children’s Hospital (RCH) and The Prince Charles Hospital 
(TPCH), Brisbane, Australia. Exclusion criteria included recent pneumothorax, haemoptysis, 
and pregnancy. Healthy, non-smoking controls (n=10) were recruited from hospital staff and 
their families. Further details are provided in the online supplementary methods. The RCH 
(HREC/11/QRCH/44), The University of Queensland (2012000615), and the Queensland 
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University of Technology Human Research Ethics Committees (1100000618) approved the 
study and participants (or their guardians) provided their written, informed consent. 
 
Clinical Measurements 
Subjects attended two study days separated by a mean (standard deviation, SD) 7.5 (4.7) days 
(range 2-21). A sputum sample was collected from each patient with CF on the day of testing. 
Cough manoeuvres were supervised by a healthcare professional and emergency equipment 
was available. 
 
Forced expiratory volume in one-second (FEV1) and forced vital capacity (FVC) were 
measured on all subjects according to ATS/ERS guidelines.[22] Respiratory muscle strength 
was measured by maximum inspiratory (MIP) and maximum expiratory (MEP) mouth 
pressures using a Micro Medical Respiratory Pressure Meter at TPCH. Weight, height, age, 
sex, and clinical status (exacerbation or clinically stable) were recorded. 
 
Determining the distance viable cough aerosols travel 
A ‘Distance Rig’ (see online supplementary methods) permitted measurement of cough 
aerosols in a particle-free environment at distances up to 4-metres from the subject (online 
supplementary figure S1).[23] An Andersen Impactor (28.3 L/min) captured and measured 
viable cough aerosol particles,[17] and a Lasair II-110 optical particle counter (OPC) 
measured real-time particle concentrations and verified the absence of room air aerosol 
contamination in the Distance Rig. Andersen Impactor and OPC samples were collected 
through a common circular isokinetic inlet. 
 
8 
 
Subjects sat with their head in the Rig breathing high-efficiency particulate air (HEPA)-
filtered air for 2-min to purge residual room air from their lungs before coughing as 
frequently and strongly as was comfortable for 5-min. The Andersen Impactor sampled 
continuously during the voluntary cough phase. Cough numbers were recorded manually. 
Cough aerosols were collected at 1, 2, and 4-metres (order randomised) from each subject, 
who performed duplicate cough manoeuvres at each distance. 
 
Determining duration of aerosol viability 
A Duration Rig (see online supplementary methods) comprised a  0·4-m3 airtight stainless 
steel cylinder (illustrated in online supplementary figure S3) to assess the duration of aerosol 
particle viability in the airborne phase. The cylinder was rotated at 1·7-rpm so that 
gravitational settling and inertial impaction of particles was minimised.[24] The system was 
flushed with HEPA-filtered air before sample collection so that cough aerosols were not 
contaminated by room air aerosols. 
 
Subjects were seated and fitted with a snorkel-style mouthpiece (CareFusion Australia) 
connected to 10-cm of flexible tubing. A nose clip was attached and subjects breathed filtered 
air for 2-min, and then coughed as much as was comfortable for 2-min, with cough numbers 
recorded manually. The Rig was isolated and the resultant cough aerosols were aged for       
5, 15, or 45-min. Suspended particles were collected with an Andersen Impactor at the 
conclusion of the ageing period. Measurements after 5 and 15-min ageing were performed in 
duplicate while, for logistic reasons, only one measurement was performed after 45-min 
ageing. 
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Microbiology 
Cough aerosol cultures were performed with chocolate bacitracin (300 mg/ml) agar using 
previously described incubation conditions and colony-forming units (CFU) count 
protocols.[17] Quantitative (sputum) and qualitative cultures were performed on respiratory 
samples using standard techniques. After presumptive screening, P. aeruginosa isolates were 
confirmed by duplex real-time (RT) polymerase chain reaction (PCR) assays.[11]                 
P. aeruginosa isolates were genotyped using enterobacterial repetitive intergenic consensus-
PCR and clusters analysed alongside a previously characterised panel of Australian shared                  
P. aeruginosa strains.[11] 
 
Statistical Analysis and Modelling of Airborne P. aeruginosa 
Continuous variables are reported as mean and SD, and binary variables as frequency and 
percentage. Analyses were performed using chi-squared test, one-way, and mixed-effects 
analysis of variance with subjects as the random factor, followed by the least significant 
difference procedure. Repeatability was estimated by intra-class correlation using a two-way 
mixed effects analysis of variance. CFU data were transformed as log(X+1) and their means 
and 95% confidence intervals (CI) were back transformed to the original units for ease of 
interpretation. We also performed a sensitivity analysis to account for the potential “stacking” 
of organisms in the cascade impactor (see online supplementary methods). P. aeruginosa 
decay over time was assessed using the Duration Rig data (5, 15, and 45-min). The half-life 
of airborne P. aeruginosa was estimated from the slope of the decay curve. A model (see 
online supplementary methods) estimated the relative effects of ventilation and airborne 
biological decay on P. aeruginosa removal in different healthcare settings, including the 
study site.[20, 25] Ventilation rates were expressed in the standard units of air changes per 
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hour (ACH), which describe how many times a volume of air equal to the volume of a room 
enters each hour. 
 
RESULTS 
Subjects were well matched for age, sex, and height, but those with CF had lower weight, 
body-mass index, and lung function (table 1). All subjects completed the cough manoeuvres 
safely. Four patients with CF were studied during a pulmonary exacerbation. Within the CF 
group there was no significant change in spirometry between study days (intraclass 
correlation coefficient [95% CI] 0.79 [0.48-0.92]). Similarly, total CFUs for P. aeruginosa in 
cough aerosols, cough counts, and log P. aeruginosa sputum concentration within subjects 
were highly repeatable (online supplementary table S1). 
 
Eighteen patients with CF produced sputum and one provided a cough swab (table 1), with  
P. aeruginosa isolated from all and 15/19 (79%) yielding at least one mucoid isolate. Sputum              
P. aeruginosa concentrations ranged from 4.0 x 106 to 4.2 x 109 CFU/mL. Genotypic analysis 
revealed 12 strains shared commonly within the Australian CF community;[11] AUST-01 
(1), AUST-02 (7), AUST-06 (2), AUST-07 (1), and AUST-19 (1), and seven unique strains. 
Five patients harboured two different strains. Other organisms cultured are detailed in table 1. 
 
P. aeruginosa was cultured in cough aerosols from all patients with CF, but not from any 
controls. Viable P. aeruginosa was isolated at 4-metres from 17/18 (94%) and at all distances 
from 16/18 (89%) of the CF group (figure 1). Aerosolised P. aeruginosa remained viable for 
45-min from 14/18 (78%) subjects in the duration experiments (figure 2). Most viable          
P. aeruginosa isolates were cultured from particles <3.3μm (table 2) and the strains cultured 
from cough aerosols were genotypically indistinguishable from those isolated in respiratory 
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samples from the same patient. Stenotrophomonas maltophilia and Arxula adeninivorans 
were also cultured in cough aerosols and sputum from two patients. No other respiratory 
pathogens cultured in sputum were isolated from cough aerosols. No P. aeruginosa or other 
microbes identified in cough aerosols were isolated from surface swabs or blank aerosol 
samples taken during the studies (see online supplementary methods). 
 
Marked inter-subject heterogeneity was seen in the total numbers of viable P. aeruginosa 
cultured from cough aerosols (figure 1; online supplementary table S2). Measured                
P. aeruginosa CFUs decreased with the distance the aerosol travelled and with the ageing 
time; CFUs were significantly higher at 1-metre than 4-metres, and at 5-min than 45-min 
(table 2). CFUs remained significantly higher for both distance and duration when corrected 
for the effects of stacking (online supplementary table S3). In both distance and duration 
studies, strong correlations were seen between total, small, and large fraction cough aerosols 
(r=0.90-1.0). A positive correlation was found between sputum and aerosol P. aeruginosa 
CFUs in both distance (r=0.73-0.78); and duration (r=0.85-0.90; online supplementary table 
S4) studies, although there was no significant correlation found between clinical or 
demographic variables and cough aerosols produced in either study. Correlations for these 
variables were unchanged when measured CFUs were corrected for stacking (online 
supplementary table S5) 
 
The influences of biological decay and room ventilation on P. aeruginosa in cough aerosols 
were modelled (see online supplementary methods). Environmental conditions in the 
Duration Rig were similar to those in the air conditioned clinical setting. The number of 
viable P. aeruginosa in cough aerosol followed an exponential decay with a half-life of 50-
min (95% CI: 30 to 151-min). Room ventilation removed additional viable P. aeruginosa and 
12 
became the dominant mechanism of removal at ventilation rates above the biological decay 
rate of the cough aerosol (i.e. approximately 0·85 ACH). Figure 3 shows the time taken to 
achieve 10, 50, 90, 99, and 99.9% reductions in airborne P. aeruginosa following the 
departure of a source patient, including the combined effects of biological decay and room 
ventilation. At 2 ACH, 90% of viable airborne P. aeruginosa are removed in approximately 
49-min (95% CI: 41 to 61-min); decreasing as ventilation rate increases to approximately   
24-min (95% CI: 22 to 26-min) at 5 ACH, and to 13-min (95% CI: 12 to 13-min) at 10 ACH. 
 
DISCUSSION 
Cross-infection between patients with CF can adversely affect health outcomes, but how this 
occurs and the transmission pathways involved remain uncertain. We have shown that 
patients with CF produce aerosols containing viable P. aeruginosa during coughing. Particles 
within the respirable range persist over distance and time, providing a potential vehicle for 
airborne transmission between patients. Marked inter-subject heterogeneity of aerosol 
production was observed, suggesting that some patients may be ‘super-spreaders’ of             
P. aeruginosa. Finally, sputum P. aeruginosa concentration was a strong predictor of viable 
cough aerosol concentrations. 
 
Evidence of highly-prevalent shared P. aeruginosa strains within CF populations suggests 
person-to-person transmission.[10, 11, 26] Using air sampling equipment both in the clinical 
setting, viable P. aeruginosa have been demonstrated close to patients with shared strain      
P. aeruginosa infection.[18, 19] The clinical significance of these findings was unclear and 
led us to study the size distribution of cough aerosols and we have previously demonstrated 
P. aeruginosa can be present in aerosols generated by coughing.[17] However, we were 
unable to determine how far these aerosols travelled or the duration they remained viable in 
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the airborne phase. An in-vitro aerosol production system has demonstrated that artificially 
produced P. aeruginosa aerosols can survive up to 45-min and that survival was greater with 
mucoid  P. aeruginosa.[20, 21] The present study confirms aerosols produced during 
coughing by infected patients contain viable P. aeruginosa that travel up to 4-metres and stay 
suspended for at least 45-min. These data add to existing evidence that airborne transmission 
is likely to play a role in patients with CF acquiring P. aeruginosa. 
 
Our study demonstrates that droplet nuclei, generated by coughing, and containing viable     
P. aeruginosa, are small enough to stay airborne for extended periods and over long 
distances. They are also well within the size range to deposit within the tracheobronchial tree 
following inhalation.[27] Such droplets can be efficiently disseminated to locations far from 
their origin by mechanical room air ventilation systems, which often recirculate up to 80-90% 
of air used for heating or cooling. The role of room ventilation as a potentiator of airborne 
transmission of microbes such as M. tuberculosis, measles, SARS-coronavirus and varicella-
zoster is well documented.[4] 
 
Published guidelines for ventilation in hospitals suggest that two ACH of fresh (i.e. non-
recirculated) air are required for clinic rooms and general wards, three ACH are 
recommended for procedure rooms, and 12 ACH are needed for isolation rooms.[28, 29] We 
have previously published results of measuring ACH in various clinical locations within 
TPCH and found that these meet or exceed recommended levels in most cases, with an 
extreme example of almost 24 ACH in an isolation room in the emergency department.[25] 
However, the data from the present study suggest that a clinic room with the recommended 
two ACH may require almost an hour after a patient harbouring P. aeruginosa leaves the 
room before 90% of the viable bacteria are removed from the air (see online supplementary 
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methods). These data have substantial implications for CF infection control practices. Our 
modelling suggests that increasing room ventilation provides some benefit, however the time 
required to remove 90% of potentially infectious aerosols still exceeds 10-min despite 
substantial increases in ACH (figure 3). A new paradigm may be needed, such as employing 
within CF centres advanced ventilation and ultraviolet germicidal irradiation (UVGI) 
techniques to achieve infection control, as is done for TB clinics.[30, 31] 
 
This study has several important limitations. The infectious inoculum required to establish   
P. aeruginosa infection in CF is unknown and may vary between patients.[20] Thus it is 
impossible to estimate to what extent viable aerosols of P. aeruginosa need to be removed to 
eliminate the risk of infection in susceptible patients. In many CF clinical settings, contact 
and droplet infection control measures have been implemented, but reduced rates of shared  
P. aeruginosa strain infections have been reported only in centres employing strict cohort 
segregation based upon molecular typing surveillance.[15] It therefore remains uncertain 
whether these simpler measures are sufficient, and if preventing airborne transmission should 
also be considered when strict segregation of large patient cohorts attending major CF centres 
is not always feasible.[14] 
 
Our study included a small number of older patients with chronic P. aeruginosa infection and 
moderately severe airflow obstruction. Thus we cannot comment on viable aerosol 
production during coughing by younger or healthier patients or in those with transient          
P. aeruginosa infections. In addition, we used culture media that selected for aerobic Gram 
negative bacteria and we cannot provide data on other microbes, including Staphylococcus 
aureus, non-tuberculous mycobacteria, or respiratory viruses.[14, 32, 33] Future studies using 
other selective media to determine the viability of other microorganisms in cough aerosols 
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are now required. Due to bactericidal effects it is also possible that the bacitracin used in the 
culture media reduced the recovery of some P. aeruginosa organisms. Finally, modelling data 
assume that the room air is perfectly mixed, which is rarely the case. As such, our estimates 
of the time taken to remove viable P. aeruginosa from a clinic room may be over- or under-
estimates of real-world scenarios (see online supplementary methods). 
 
The present study uses bacterial infection in patients with CF to demonstrate the potential for 
aerosol transmission in healthcare settings and adds to studies suggesting similar mechanisms 
for M. tuberculosis and for B. pertussis in non-human primate models.[5, 6] Our results 
provide further evidence which challenges the dogma that CF bacterial pathogens within 
droplet nuclei have limited survival in air. Indeed, airborne transmission may be a more 
important mechanism of cross-infection within the CF community than previously considered 
to be the case. Furthermore, our data add to the controversy generated by the current USA CF 
Foundation guidelines that only one person with CF attend a CF Foundation-sponsored or CF 
Centre-sponsored event;[34] recommendations strongly opposed by some adults with CF.[35] 
 
In summary, this study indicates that when patients with CF harbouring P. aeruginosa cough 
they produce an aerosol containing viable organisms capable of travelling 4-metres and 
persisting in the air for 45-min. These data challenge current CF infection control guidelines 
which remain in place in many parts of the world including the separation of patients by 1-to-
2 metres to prevent cross-infection by respiratory bacteria.[13, 36] Consequently, further 
studies on transmission are needed and infection control practices recommended currently for 
the CF community may need to be re-evaluated. 
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FIGURE LEGENDS 
 
Figure 1. Log10 combined total colony-forming unit (CFU) counts of Pseudomonas 
aeruginosa isolated at 1, 2 and 4-metres from the Distance Rig cough aerosol cultures of 
subjects with cystic fibrosis. 
 
Figure 2. Log10 combined total colony-forming unit (CFU) counts of Pseudomonas 
aeruginosa isolated after 5, 15 and 45-minutes from the Duration Rig cough aerosol cultures 
of subjects with cystic fibrosis. 
 
Figure 3. Time taken to achieve 10, 50, 90, 99, and 99.9 percent reductions in airborne 
Pseudomonas aeruginosa due to the combined effects of biological decay and room 
ventilation. 
 
17 
 
Table 1. Demographic, clinical and microbiological characteristics of the study subjects at time of initial 
cough aerosol experiment, according to type of subject.* 
Characteristic Subjects with cystic fibrosis (N=19) 
Healthy control 
subjects (N=10) P-Value 
Age - years 25.8±9.2 26.5±8.7 0.85 
   (range) 14.4-43.4 16.1-41.5  
Male sex − no. (%) 10 (52.6) 4 (40.0) 0.52 
Weight − kilograms 63.0±11.7 74.5±16.1 0.04 
Height − centimetres 169.6±6.7 173.3±1.9 0.30 
Body-mass index 21.8±3.1 24.6±2.9 0.03 
FEV1    
       Value − litres 2.03±0.70 3.80±0.80 <0.001 
       Percent of predicted value 53.9±19.0 96.1±11.5 <0.001 
FVC     
       Value - litres 3.23±0.69 4.68±0.98 <0.001 
       Percent of predicted value 72.9±15.9 100.2±9.2 <0.001 
MIP†    
       Value − cmH2O 105.78±27.38 95.12±19.13 0.38 
       Percent of predicted value 116.7±30.6 108.4±18.1 0.53 
MEP†     
       Value − cmH2O 126.23±31.67 130.15±28.91 0.79 
       Percent of predicted value 108.5±24.0 112.7±23.3 0.72 
Number of coughs per minute 26.9±18.5 37.8±23.5 0.18 
Infection − no. (%)    
Pseudomonas aeruginosa 19 (100.0) - - 
           Mucoid P. aeruginosa 15 (78.9) - - 
           Non-mucoid P. aeruginosa 18 (94.7) - - 
Staphylococcus aureus 5 (26.3) - - 
Stenotrophomonas maltophilia 2 (10.5) - - 
Trichosporon/Arxula spp. 3 (15.8)   
Aspergillus spp. 3 (15.8) - - 
Scedosporium spp. 2 (10.5) - - 
Candida spp. 1 (5.7) - - 
Sputum P. aeruginosa concentration − 
colony-forming units per milliletre‡ 
1.37 x 108                                                                           
(2.16 x 107 - 1.06 x 109) 
- - 
*Values are means ± SD unless otherwise indicated. †Maximal static inspiratory and expiratory mouth pressures 
(MIPS and MEPS) were calculated for only 12/19 test subjects and 7/10 control subjects. ‡Data are presented as 
median values (interquartile range). Only 18/19 test subjects were able to expectorate sputum on the initial 
experimental day. 
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Table 2. Colony-forming unit (CFU) counts of Pseudomonas aeruginosa isolated from the cough aerosol 
cultures of subjects with cystic fibrosis. CFUs in total aerosol, and in large and small particle fractions 
are shown* 
Distance 1 metre 2 metres 4 metres ANOVA P-value† 
Total‡ 52.6 (40.9-67.6)a 37.3 (28.9-48.0)a 24.8 (19.2-32.0)b 0.001 
Large fraction§ 27.4 (21.4-34.9)a 19.9 (15.5-25.5)a 12.6 (9.7-16.2)b <0.001 
Small fraction¶ 27.6 (21.2-35.9)a 19.6 (15.0-25.5)ab 14.3 (10.9-18.7)b 0.005 
     
Duration 5 minutes 15 minutes 45 minutes  
Total‡ 14.6 (11.0-19.2)a 11.9 (8.9-15.7)a 7.7 (5.4-11.0)b 0.046 
Large fraction§ 4.2 (3.1-5.5)a 3.9 (2.9-5.2)a 2.3 (1.5-3.4)a 0.074 
Small fraction¶ 11.9 (9.1-15.6)a 9.0 (6.7-11.8)ab 6.2 (4.3-8.8)b 0.031 
*Values are means (95% CI). Within sets and rows a different superscript letter (a or b) denotes a 
significant difference (P<0·05) between other distances or durations. †ANOVA for trend across distance or 
duration. ‡Total CFU counts represent the P. aeruginosa CFUs isolated from all six Andersen Impactor 
Stages (aerosol particles sizes 0.65 to >7.0 µm). §Large particle fraction CFU counts represent the  
P. aeruginosa CFUs isolated from Stages 1, 2, and 3 (aerosol particle sizes >7, 4.7-7.0 and 3.3-4.7 µm, 
respectively) of the Andersen Impactor. ¶Small particle fraction CFU counts represent the P. aeruginosa 
CFUs isolated from Stages 4, 5, and 6 (aerosol particle sizes 2.1-3.3, 1.1-2.1 and 0.65-1.1 µm, respectively) 
of the Andersen Impactor. 
 
19 
ACKNOWLEDGEMENTS 
The study was funded by grants from The Prince Charles Hospital Foundation, Children’s 
Health Foundation Queensland, Institute of Health and Biomedical Innovation-Queensland 
University of Technology (Collaborative Research Development Grant Scheme to LM, LDK 
and GRJ; Early Career Researchers Grant to GRJ), Australian Research Council Discovery 
Grant to LM (DP0558410), Perpetual Philanthropy, Queensland Health Office of Health and 
Medical Research (Health Fellowships for PDS, CEW and SCB), National Health and 
Medical Research Council (NHMRC) Early Career (Australian Public Health) Fellowship to 
LDK (#1036620), and a NHMRC Australia Senior Principal Research Fellowship 
(#1002035) to PDS. We are grateful to all the participants and research nursing staff 
including Andrea Beevers (The Prince Charles Hospital, Brisbane), Sue Edwards, Rebecca 
Jackson, Heather Saddington and Emma Sanderson (Royal Children’s Hospital, Brisbane) for 
the support in subject preparation and supervision during studies. We thank Dr Boris Polak 
from the Sir Albert Sakzewski Virus Research Centre and Clinical Medical Virology Centre, 
The University of Queensland for his assistance preparing the Online Supplementary Figures. 
 
CONTRIBUTORS 
LDK, GRJ, TJK, LM and SCB contributed equally to the work. LDK, GRJ, KG, PDS, CEW, 
LM, and SCB conceived the study and led the funding application. All authors contributed to 
the experimental design and management of the study. LDK and GRJ supervised by LM led 
the development and verification of the sampling Rigs and collection of the cough aerosol 
samples. JC, MW, CEW, and SCB contributed to subject recruitment and collection of 
clinical data and samples. TJK, JAK and KAR led the microbiological sampling, culture, 
identification, and genotyping. PKO led the statistical analyses. Manuscript was written by 
LDK, TJK, PDS, and SCB, with input from co-authors. SCB had full access to all of the data 
20 
in the study and takes responsibility for the integrity of the data and the accuracy of the data 
analysis. 
 
COMPETING INTERESTS 
The authors have no competing interests to declare. 
 
FUNDING 
The study was funded by grants from The Prince Charles Hospital Foundation, Children’s 
Health Foundation Queensland, Institute of Health and Biomedical Innovation-Queensland 
University of Technology (Collaborative Research Development Grant Scheme to LM, LDK 
and GRJ; Early Career Researchers Grant to GRJ), Australian Research Council Discovery 
Grant to LM (DP0558410), Perpetual Philanthropy, Queensland Health Office of Health and 
Medical Research (Health Fellowships for PDS, CEW and SCB), National Health and 
Medical Research Council (NHMRC) Early Career (Australian Public Health) Fellowship to 
LDK (#1036620) and a NHMRC Australia Senior Principal Research Fellowship (#1002035) 
to PDS. 
 
EXCLUSIVE LICENSE 
The Corresponding Author of this article contained within the original manuscript (which 
includes without limitation any diagrams photograph s, other illustrative material, video, film 
or any other material howsoever submitted by any of the contributor(s) at any time and 
related to this article), has the right to grant on behalf of all authors and does grant on behalf 
of all authors, a full copyright assignment to Thorax as set out in the copyright assignment 
at: http://group.bmj.com/products/journals/instructions?for?authors/licence?forms. 
21 
REFERENCES 
1. Birnbaum HG, Morley M, Greenberg PE, et al. Economic burden of respiratory 
infections in an employed population. Chest 2002;122(2):603-11. 
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 
causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the 
Global Burden of Disease Study 2010. Lancet 2012;380(9859):2095-128. 
3. Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for isolation precautions: 
preventing transmission of infectious agents in health care settings. Am J Infect 
Control 2007;35(10 Suppl 2):S65-164. 
4. Li Y, Leung GM, Tang JW, et al. Role of ventilation in airborne transmission of 
infectious agents in the built environment - a multidisciplinary systematic review. 
Indoor Air 2007;17(1):2-18. 
5. Jones-Lopez EC, Namugga O, Mumbowa F, et al. Cough aerosols of Mycobacterium 
tuberculosis predict new infection: a household contact study. Am J Respir Crit Care 
Med 2013;187(9):1007-15. 
6. Warfel JM, Beren J, Merkel TJ. Airborne transmission of Bordetella pertussis. J 
Infect Dis 2012;206(6):902-6. 
7. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373(9678):1891-904. 
8. Courtney JM, Bradley J, McCaughan J, et al. Predictors of mortality in adults with 
cystic fibrosis. Pediatr Pulmonol 2007;42(6):525-32. 
9. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early 
Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138(5):699-704. 
10. Fothergill JL, Walshaw MJ, Winstanley C. Transmissible strains of Pseudomonas 
aeruginosa in cystic fibrosis lung infections. Eur Respir J 2012;40:227-38. 
22 
11. Kidd TJ, Ramsay KA, Hu H, et al. Shared Pseudomonas aeruginosa genotypes are 
common in Australian cystic fibrosis centres. Eur Respir J 2013;41(5):1091-100. 
12. Armstrong DS, Nixon GM, Carzino R, et al. Detection of a widespread clone of 
Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care 
Med 2002;166(7):983-7. 
13. Cystic Fibrosis Australia. Infection control guidelines for cystic fibrosis patients and 
carers. 2nd ed. Sydney: Cystic Fibrosis Australia, 2012:13. 
14. Saiman L. Infection prevention and control in cystic fibrosis. Curr Opin Infect Dis 
2011;24(4):390-5. 
15. Griffiths AL, Jamsen K, Carlin JB, et al. Effects of segregation on an epidemic 
Pseudomonas aeruginosa strain in a cystic fibrosis clinic. Am J Respir Crit Care Med 
2005;171(9):1020-5. 
16. Jones AM, Dodd ME, Govan JR, et al. Prospective surveillance for Pseudomonas 
aeruginosa cross-infection at a cystic fibrosis center. Am J Respir Crit Care Med 
2005;171(3):257-60. 
17. Wainwright CE, France MW, O'Rourke P, et al. Cough-generated aerosols of 
Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic 
fibrosis. Thorax 2009;64(11):926-31. 
18. Jones AM, Govan JR, Doherty CJ, et al. Identification of airborne dissemination of 
epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a 
cross infection outbreak. Thorax 2003;58(6):525-7. 
19. Panagea S, Winstanley C, Walshaw MJ, et al. Environmental contamination with an 
epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and 
study of its survival on dry surfaces. J Hosp Infect 2005;59(2):102-7. 
23 
20. Clifton IJ, Fletcher LA, Beggs CB, et al. An aerobiological model of aerosol survival 
of different strains of Pseudomonas aeruginosa isolated from people with cystic 
fibrosis. J Cyst Fibros 2010;9(1):64-68. 
21. Clifton IJ, Fletcher LA, Beggs CB, et al. A laminar flow model of aerosol survival of 
epidemic and non-epidemic strains of Pseudomonas aeruginosa isolated from people 
with cystic fibrosis. BMC Microbiol 2008;8(1):105. 
22. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function 
tests. Eur Respir J 2005;26(5):948-68. 
23. Morawska L, Johnson G, Ristovski Z, et al. Size distribution and sites of origin of 
droplets expelled during expiratory activities. J Aerosol Sci 2009;40(3):256-69. 
24. Goldberg LJ. Naval biomedical research laboratory, programmed environment, 
aerosol facility. Appl Microbiol 1971;21(2):244-52. 
25. Knibbs LD, Morawska L, Bell SC, et al. Room ventilation and the risk of airborne 
infection transmission in 3 health care settings within a large teaching hospital. Am J 
Infect Control 2011;39(10):3546-51. 
26. Aaron SD, Vandemheen KL, Ramotar K, et al. Infection with transmissible strains of 
Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 
2010;304(19):2145-53. 
27. Tellier R. Review of aerosol transmission of influenza A virus. Emerg Infect Dis 
2006;12(11):1657-62. 
28. Beggs CB, Kerr KG, Noakes CJ, et al. The ventilation of multiple-bed hospital wards: 
review and analysis. Am J Infect Control 2008;36(4):250-9. 
29. Sehulster LM, Chinn RYW, Arduino MJ, et al. Guidelines for environmental 
infection control in health-care facilities. Recommendations from CDC and the 
24 
Healthcare Infection Control Practices Advisory Committee (HICPAC). Chicago: 
American Society for Healthcare Engineering/American Hospital Association, 2004. 
30. Nardell EA, Bucher SJ, Brickner PW, et al. Safety of upper-room ultraviolet 
germicidal air disinfection for room occupants: results from the Tuberculosis 
Ultraviolet Shelter Study. Public Health Rep 2008;123(1):52-60. 
31. Centers for Disease Control and Prevention. Guidelines for Preventing the 
Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005. MMWR 
2005;54(RR-17):1-144. 
32. Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify 
transmission of Mycobacterium abscessus between patients with cystic fibrosis: a 
retrospective cohort study. Lancet 2013;381(9877):1551-60. 
33. Gralton J, Tovey ER, McLaws ML, et al. Respiratory virus RNA is detectable in 
airborne and droplet particles. J Med Virol 2013;85(12):2151-9. 
34. Jain M, Saiman LM, Sabadosa K, et al. Point: Does the risk of cross-infection warrant 
exclusion of adults with cystic fibrosis from Cystic Fibrosis Foundation events? Yes. 
Chest 2013;doi:10.1378/chest.13-2404. 
35. Shepherd SL, Goodrich EJ, Desch J, et al. Counterpoint: Does the risk of cross-
infection warrant exclusion of adults with cystic fibrosis from Cystic Fibrosis 
Foundation events? No. Chest 2013;doi:10.1378/chest.13-2406. 
36. Saiman L, Siegel J. Infection control recommendations for patients with cystic 
fibrosis: microbiology, important pathogens, and infection control practices to prevent 
patient-to-patient transmission. Infect Control Hosp Epidemiol 2003;24(5 Suppl):S6-
52. 
 
 
25 
ONLINE SUPPLEMENTARY MATERIAL 
 
 
VIABILITY OF PSEUDOMONAS AERUGINOSA IN COUGH AEROSOLS GENERATED BY PERSONS WITH 
CYSTIC FIBROSIS. 
 
 
Luke D. Knibbs, Graham R. Johnson, Timothy J. Kidd, Joyce Cheney, Keith Grimwood, Jacqueline A. 
Kattenbelt, Peter K. O’Rourke, Kay A. Ramsay, Peter D. Sly, Claire E. Wainwright, Michelle E. Wood, 
Lidia Morawska and Scott C. Bell 
 
 
  
26 
METHODS 
Recruitment 
Subjects with CF were recruited from the two CF centres by personal invitation from the 
Investigators (SCB, CEW) or the Study Coordinators (MEW, JC). All CF patients were   >12-years of 
age, had chronic Pseudomonas aeruginosa infection and at least one positive sputum culture in the 
prior 12-months. The majority of patients were studied during clinical stability, however, four 
patients were studied close to the completion of intravenous antibiotics for logistic reasons (e.g. 
travelling long distance, avoid missing school attendance). Healthy control participants were 
recruited from contact with staff at both healthcare facilities including relatives of the staff for the 
younger controls. Nineteen CF patients with CF and 10 healthy controls participated. Two patients 
and two controls performed only one of the experiment days. 
 
Distance of cough aerosols: ‘Distance Rig’ 
The Distance Rig consisted of an expandable wind tunnel that allowed high-efficiency particulate air 
(HEPA)-filtered air to be introduced upstream of the subject;[1] ensuring unidirectional air flow of 
particle-free air and permitting measurement of cough aerosols at distances of 0 to 4-metres from 
the subject without interference from other particle sources (Figure E1). The air velocity was 
maintained at 0.1-metres/sec, typical of a mechanically-ventilated indoor environment, such as a 
hospital.[2-4] The Rig was positively pressurized to prevent room air contamination. 
 
Viable aerosol and total particle sampling methods 
A six-stage Andersen Impactor (Thermo Scientific, Franklin, MA) captured and sized viable cough 
aerosols in the six stages between 0.6 and >7 µm.[5] A vacuum pump was used to draw 28.3 L/min 
of air through the Impactor. The pump flow was checked daily using a rotameter, and all Andersen 
Impactor O-rings were inspected for wear. Exhaust air from the pump was HEPA-filtered. 
 
A Lasair II-110 (Particle Measuring Systems, Boulder, CO) optical particle counter (OPC) measured 
real-time particle concentration in six channels between 0.1 and >5 µm using a sample flow of 28.3 
L/min, permitting detection of very low concentrations. The OPC verified that there were no room 
air particles present before each test, subjects’ lungs were free of residual room air, and no 
contamination of aerosols occurred during testing. It also confirmed that the total particle 
concentration in the Rig was <0.01 particles per cm3 (p/cc) prior to the subject coughing, which was 
approximately 104 times lower than the room air concentration and similar to an ISO 4 cleanroom. 
 
The Andersen Impactor and OPC samples were collected through a common 12.5 cm circular, sharp-
edged isokinetic inlet. It was set parallel to the airflow and provided 100% particle aspiration 
efficiency at the tunnel air velocity of 0.1 metres/sec.[6] Smoke visualization tests confirmed sample 
extraction by the inlet was uniform. One metre of conductive tubing transported samples from the 
inlet to the Andersen Impactor and OPC. The tubing residence time was 1-sec for Andersen samples 
and 0.06-sec for OPC samples. Sample losses due to gravitational settling and inertial impaction 
were from 0 to 8% and 0 to 1%, respectively, and diffusion losses were negligible.[6] 
 
Air velocity was monitored continuously using a 9535 hot-wire anemometer (TSI Inc., St. Paul, MN). 
Temperature and water vapour concentration were measured simultaneously upstream of the 
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participant and at the sampling inlet by HC2-CO4 probes and a HygroLog NT data logger (Rotronic 
AG, Bassersdorf). 
 
Duration of cough aerosols: ‘Duration Rig’ 
A 0.4 metre3 airtight stainless steel cylinder was used for collecting and aging cough aerosols to 
assess viability in the airborne phase (Figure E2). A variable-speed drive was used to set the rotation 
rate (1.7 rpm) of the Rig, which minimized gravitational settling and inertial impaction of particles.[7, 
8] The system was flushed with HEPA-filtered air before sample collection so that cough aerosols 
were prevented from being contaminated by room air aerosols. 
 
Viable aerosol and total particle sampling methods 
The Andersen Impactor and OPC described previously were used during sampling. We estimate over 
95% of cough aerosol particles in the size range of the Andersen Impactor remained airborne during 
the aging period.[9] 
 
An 8-cm circular inlet was positioned 30-cm inside the Rig along the rotation axis. This provided 
100% aspiration efficiency of particles in the Andersen and OPC size ranges.[6] Samples were 
transported via straight conductive tubing, with residence times of 0.8 sec for Andersen samples and 
0.09 sec for OPC samples. Sample losses across the Andersen Impactor size range due to 
gravitational settling and inertial impaction were from 0 to 6% and 0 to 1%, respectively. 
Temperature and water vapour concentration were measured simultaneously inside and outside of 
the Duration Rig by the same probes described above. 
 
 
Before each test, the Duration Rig was flushed with HEPA-filtered air using a 3M Air-Mate respirator 
(St. Paul, MN). Once the OPC confirmed a particle concentration <0.01 p/cc, a     5-minute blank 
sample was taken by the Andersen Impactor. The Air-Mate provided filtered air to replace that 
extracted by the pump. The OPC confirmed the Rig was free of contamination, and the Rig was then 
isolated by entry and exit valves. 
 
Cleaning and quality assurance 
The Distance and Duration Rigs were disinfected thoroughly at the end of each study day using 
0.15% (w/v) benzalkonium chloride (GlitzTM, Pascoe’s Pty Ltd, Australia), followed by 70% (v/v) 
ethanol. HEPA-filtered air dried both devices. Non-disposable items, collection tubes, inlet valves 
and other rigging devices were sterilized using standard hospital procedures. Andersen Impactors 
were decontaminated with 70% (v/v) ethanol and air dried. Surface swabs were collected into Amies 
Agar Gel Transport Medium (COPAN Diagnostics Inc., CA, USA) and blank aerosol samples were 
collected at the start and end of each day. For Duration studies, additional blank aerosol samples 
were collected between each experiment. 
 
Quality assurance surface swabs were enriched in LB broth (Sigma-Aldrich Pty Ltd, New South Wales, 
Australia) for 24-hours, and then subcultured onto chocolate bacitracin and colistin nalidixic acid 
agar (Thermo Fisher Scientific Australia Pty Ltd, Victoria, Australia) at 350C for 72 hours, and 
Sabouraud agar (Thermo Fisher Scientific Australia Pty Ltd) at 280C for 72 hours. Blank aerosol 
samples were incubated aerobically at 350C for 72-hours. 
28 
 
 
 
Modelling of airborne Pseudomonas aeruginosa 
To estimate the time taken to remove airborne P. aeruginosa following the departure of a source 
patient, we used a simple model based on the airborne biological inactivation rate we measured 
experimentally combined with a range of room ventilation rates.[10] This approach assumed that 
these were the two major mechanisms by which airborne P. aeruginosa was removed; biological 
inactivation (i.e. ‘die-off’) and dilution with room ventilation air.[10] Our modelling focussed solely 
on the risk posed by airborne cough aerosol droplet nuclei containing P. aeruginosa, as distinct from 
contact or droplet transmission, as this is the transmission mode affected by these removal 
processes. 
 
The role of airborne biological decay and room air ventilation was considered to be negligible in 
determining the fate of particles in the size range collected by the first (i.e. ‘input’) stage of the 
viable sampler. This input stage collects particles >7µm and such droplet nuclei were not considered 
to fall within the airborne size range (Dp <5µm) for the purposes of this study. The decision to 
exclude the larger droplet nuclei is further supported by the expectation that droplet nuclei form 
initially as much larger droplets before drying to their equilibrium size and collection by the viable 
sampler. That initial size is approximately twice the diameter of the droplet residue collected by the 
viable sampler.[11] The smaller surface area to mass ratios of these larger particles results in the 
droplets’ movement and fate being dominated by momentum acquired within the cough exhalation 
jet and the influence of gravity immediately after the cough. Because of these influences the larger 
droplets and droplet residues tend to impact on surfaces during, or soon after, the cough event so 
that they do not remain airborne long enough to have their fate altered significantly by the 
ventilation and room air currents.[12-14] Hence, deposition of particles is not incorporated into 
airborne models. While we observed small numbers of viable particles on the input stage of the 
viable sampler following extended storage, this was mostly due to the counteraction of the 
gravitational settling process provided by the Duration Rig.[9] Thus, under ‘real world’ conditions, 
particles in the size range of the Andersen Impactor input stage would deposit due to gravitational 
settling very shortly after their release, in contrast to those in the airborne range, which remain 
suspended for extended periods.[14] We therefore considered the particles collected on the input 
stage to not be relevant to our modelling. 
 
Empirically, the effect of ventilation on the concentration of airborne pathogens, or indeed any 
particle, over time follows a first-order exponential decay.[11, 15] Likewise, the biological 
inactivation of a pathogen in response to environmental challenges is represented in the same 
manner.[11] Therefore, the concentration of P. aeruginosa at a given point in time can be calculated 
using equation 1: 
 
 log𝑒(𝑁𝑡) = log𝑒(𝑁0) − (𝑘𝑏𝑖𝑜 + 𝑘𝑣𝑒𝑛𝑡) × 𝑡  (1)1 
Where: 
 𝑁𝑡  = 𝑃.𝑎𝑒𝑟𝑢𝑔𝑖𝑛𝑜𝑠𝑎 concentration at time 𝑡 (CFU L−1) 
 𝑁0 =  𝑃.𝑎𝑒𝑟𝑢𝑔𝑖𝑛𝑜𝑠𝑎 concentration at time 0 (CFU L−1) 
 𝑘𝑏𝑖𝑜 = biological inactivation rate of 𝑃.𝑎𝑒𝑟𝑢𝑔𝑖𝑛𝑜𝑠𝑎 (ℎ−1) 
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 𝑘𝑣𝑒𝑛𝑡 = removal of 𝑃.𝑎𝑒𝑟𝑢𝑔𝑖𝑛𝑜𝑠𝑎 due to room ventilation rate (ACH−1) 
 𝑡 = time (h) 
 
A practical example of when to employ such models is when seeking to adhere to the US Centers for 
Disease Control and Prevention recommendation of allowing sufficient time for ≥99% removal of 
airborne contaminants following the departure of a patient with suspected or confirmed 
tuberculosis from a room before another patient enters.[16] 
Similarly, the model can help determine the time required to achieve a specified reduction in 
airborne P. aeruginosa in a CF clinic setting by taking into account the known room ventilation rate. 
Figure 3 in the paper shows that it would take approximately 50-min to achieve this removal, due to 
combined effect of ventilation and biological inactivation, in a clinic room ventilated at the guideline 
rate of two ACH.[17-19] Figure 3 also shows the time taken to remove specified amounts of P. 
aeruginosa at the ventilation guidelines prescribed for other clinical settings.[17] 
 
In addition to assuming that ventilation and biological decay are the major mechanisms which 
remove airborne P. aeruginosa from room air, we made two other key assumptions that underpin 
equation 1 and its use that affect the accuracy of our predictions. Firstly, and most importantly, the 
pathogen is assumed to be to be perfectly mixed with the room air, which is almost never the case in 
practice.[17] There are regions where the concentration can be higher or lower than that assumed 
under perfect mixing. For example, this could occur due to proximity of the pathogen source or a 
room ventilation inlet, respectively. However, this assumption is characteristic of all the classic 
airborne transmission models.[17] If a conservative approach to infection control is required, then it 
is appropriate to err towards a greater amount of pathogen removal, such as 90%, to account for 
this when determining how long to wait before the next person enters a room. 
 
Secondly, as the majority of ventilation air is usually recirculated it is prudent to base estimates of 
room clearance on only the outdoor air component of ventilation air, which is the method we have 
used to present the estimates in this paper.[20] For example, if 25% of air supplied to a room is 
‘fresh’ outdoor air and the total ventilation rate is 8 ACH, then the outdoor air exchange rate is 2 
ACH and this is the appropriate figure to use when modelling or reading off Figure 3 in the paper. 
Likewise, ventilation guidelines for healthcare settings often specify a minimum total ventilation rate 
and the proportion that must be outdoor air (e.g. 6 ACH total with at least 2 ACH outdoor). In 
assessing a room ventilated at these guideline values, the ventilation rate would be set to 2 ACH, 
rather than 6. This approach considers all recirculated ventilation air as contaminated and incapable 
of diluting the concentration of a pathogen. While this may not be the case in practice, particularly 
where recirculated air is filtered, it allows for conservative exposure risks to be determined. This 
method has its basis in the enduring work of Riley and colleagues in revisiting the earlier work of 
Wells, and developing what is now known as the Wells-Riley equation for estimating the probability 
of airborne pathogen transmission indoors.[21, 22] As the infectious inoculum of P. aeruginosa is 
unknown, it is appropriate to employ this conservative approach to infection control. 
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Table S1. Repeatability of log transformed combined total colony-forming units (CFU) of 
Pseudomonas aeruginosa, total number of coughs, FEV1 actual and log10 sputum P. aeruginosa 
in subjects with cystic fibrosis. 
  Experiment Repeatability 95% CI 
Combined total Distance 0.92 0.86 - 0.97 
 Duration 0.89 0.79 - 0.96 
Total number of coughs Distance 0.95 0.90 - 0.98 
 Duration 0.95 0.91 - 0.98 
FEV1 actual  0.79 0.48 - 0.92 
log10 sputum P. aeruginosa   0.71 0.35 - 0.89 
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Table S2. Comparison of between subjects, within subjects, duplicates and ratios for log transformed small, large and combined total particle 
fraction colony-forming units (CFU) of Pseudomonas aeruginosa isolated from the cough aerosol cultures of subjects with cystic fibrosis and 
the number of coughs per minute in distance and duration experiments. 
Characteristic Between subjects Within subjects Duplicates Between/Within Ratio 
Between/Duplicates 
Ratio 
Distance      
Small 21.5 0.6 0.2 38.1 99.4 
Large 21.8 0.5 0.2 44.7 113.9 
Combined total 24.6 0.5 0.3 46.5 112.8 
Number of coughs 1245.6 20.6 6.6 60.6 189.9 
      
Duration      
Small 16.8 0. 6 0.3 32.9 56.6 
Large 9.8 0.5 0.2 22.3 47.1 
Combined total 17.8 0.6 0.3 31.9 69.4 
Number of coughs 1523.3 14.8 20.5 100.6 74.3 
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Table S3. Colony-forming unit (CFU) counts of Pseudomonas aeruginosa, corrected for stacking, 
isolated from the cough aerosol cultures of subjects with cystic fibrosis. CFUs in total aerosol, and in 
large and small particle fractions are shown*. 
Distance 1 metre 2 metres 4 metres ANOVA P-value† 
Total‡ 59.3 (45.6 – 77.0)a 39.4 (30.2-51.3)b 26.3 (20.1-34.3)c 0.001 
Large fraction§ 30.2 (23.4-38.9)a 21.0 (16.2-27.1)b 13.2 (10.1-17.2)c <0.001 
Small fractionǁ 31.7 (24.0-41.7)a 20.8 (15.6-27.5)b 15.3 (11.5-20.3)b 0.003 
     
Duration 5 minutes 15 minutes 45 minutes  
Total‡ 15.2 (11.4-20.1)a 12.3 (9.2-16.4)a 7.9 (5.5-11.3)b 0.043 
Large fraction§ 4.3 (3.2-5.7)a 4.0 (2.9-5.3)a 2.3 (1.5-3.4)a 0.073 
Small fractionǁ 12.5 (9.5-16.5)a 9.3 (7.0-12.3)ab 6.4 (4.4-9.1)b 0.029 
 
* Values are means (95% CI). Within sets and rows a different superscript letter (a or b or c) denotes a 
significant difference (P<0.05) between other distances or durations. 
† ANOVA for trend across distance or duration  
‡ Total CFU counts represent the P. aeruginosa CFUs isolated from all six Andersen Impactor Stages 
(aerosol particles sizes 0.65 to >7.0 µm). 
§ Large particle fraction CFU counts represent the P. aeruginosa CFUs isolated from Stages 1, 2 and 3 
(aerosol particle sizes >7, 4.7-7.0 and 3.3-4.7 µm, respectively) of the Andersen Impactor. 
ǁ Small particle fraction CFU counts represent the P. aeruginosa CFUs isolated from Stages 4, 5 and 6 
(aerosol particle sizes 2.1-3.3, 1.1-2.1 and 0.65-1.1 µm, respectively) of the Andersen Impactor. 
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Table S4. Correlation between clinical characteristics, number of coughs performed, sputum Pseudomonas aeruginosa 
concentration and log transformed combined total colony-forming units of P. aeruginosa isolated from the cough aerosol 
cultures of subjects with cystic fibrosis. 
Characteristic 
Pearson correlation coefficient 
1 metre 2 metres 4 metres 5 minutes 15 minutes 45 minutes 
Age -0.05 -0.2 -0.25 0.02 -0.02 -0.11 
Body-mass index -0.37 -0.46 -0.36 -0.16 -0.19 -0.24 
FEV1 Value - litres 0.08 0.22 0.21 -0.12 0.08 0.06 
FEV1 Percent of predicted value 0.09 0.25 0.22 0.02 0.24 0.23 
FVC Value - litres 0.05 0.13 0.16 -0.22 -0.07 -0.11 
FVC Percent of predicted value 0.07 0.2 0.2 0 0.18 0.17 
MIP Value - cmH2O -0.1 -0.14 -0.16 -0.29 -0.33 -0.36 
MIP Percent of predicted value -0.31 -0.26 -0.28 -0.34 -0.35 -0.27 
MEP Value - cmH2O 0.27 0.29 0.22 0.12 0.14 0.05 
MEP Percent of predicted value -0.15 -0.02 -0.09 -0.22 -0.12 -0.06 
Number of coughs performed -0.05 0.04 -0.09 0.23 0.26 0.26 
Sputum P. aeruginosa concentration 0.73* 0.73* 0.78† 0.90† 0.85† 0.85† 
 
* Correlations achieving statistical significance of 0.01. 
† Correlations achieving statistical significance of <0.01. 
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Table S5. Correlation between clinical characteristics, number of coughs performed, sputum Pseudomonas aeruginosa 
concentration and log transformed combined total colony-forming units of P. aeruginosa corrected for stacking isolated 
from the cough aerosol cultures of subjects with cystic fibrosis. 
Characteristic 
Pearson correlation coefficient 
1 metre 2 metres 4 metres 5 minutes 15 minutes 45 minutes 
Age -0.06 -0.20 -0.26 0.02 -0.02 -0.10 
Body-mass index -0.37 -0.46 -0.36 -0.16 -0.19 -0.23 
FEV1 Value - litres 0.08 0.22 0.21 -0.12 0.07 0.06 
FEV1 Percent of predicted value 0.10 0.25 0.22 0.03 0.23 0.22 
FVC Value - litres 0.05 0.13 0.16 -0.22 -0.08 -0.12 
FVC Percent of predicted value 0.08 0.20 0.21 0.00 0.17 0.16 
MIP Value - cmH2O -0.10 -0.14 -0.16 -0.29 -0.33 -0.36 
MIP Percent of predicted value -0.28 -0.26 -0.26 -0.33 -0.35 -0.27 
MEP Value - cmH2O 0.24 0.27 0.20 0.12 0.14 0.05 
MEP Percent of predicted value -0.13 -0.01 -0.08 -0.21 -0.12 -0.06 
Number of coughs performed -0.05 0.04 -0.09 0.24 0.26 0.26 
Sputum P. aeruginosa concentration 0.71* 0.73* 0.77† 0.90† 0.85† 0.85† 
 
* Correlations achieving statistical significance of 0.01. 
† Correlations achieving statistical significance of <0.01. 
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Figure S1. Schematic diagram of the Distance Rig. 
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Figure S2. Schematic diagram of the Duration Rig. 
 
 
